CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 39 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-20 | Biondi Paul Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2020-01-29 | Shaff Eric D. President CFO | Grant or award · STOCK OPTION (RIGHT TO BUY) | +1,000,000 | 1,000,000 | ||
| 2020-01-29 | Chapman Marcus | Grant or award · STOCK OPTION (RIGHT TO BUY) | +125,000 | 125,000 | ||
| 2020-01-29 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · STOCK OPTION (RIGHT TO BUY) | +350,000 | 350,000 | ||
| 2020-01-29 | Henn Matthew R. | Grant or award · STOCK OPTION (RIGHT TO BUY) | +300,000 | 300,000 | ||
| 2020-01-29 | Aunins John G. Chief Technology Officer & EVP | Grant or award · STOCK OPTION (RIGHT TO BUY) | +300,000 | 300,000 | ||
| 2020-01-26 | Shaff Eric D. CEO and President | Exercise or conversion | +20,000 | 32,842 | ||
| 2020-01-26 | Shaff Eric D. CEO and President | Exercise or conversion · RESTRICTED STOCK UNITS | −20,000 | 0 | ||
| 2020-01-26 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion | +25,000 | 41,054 | ||
| 2020-01-26 | DesRosier Thomas Chief Legal Officer and EVP | Exercise or conversion · RESTRICTED STOCK UNITS | −25,000 | 0 | ||
| 2020-01-26 | Henn Matthew R. | Exercise or conversion | +7,500 | 12,000 | ||
| 2020-01-26 | Henn Matthew R. | Exercise or conversion · RESTRICTED STOCK UNITS | −7,500 | 0 | ||
| 2020-01-26 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion | +12,500 | 105,250 | ||
| 2020-01-26 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion · RESTRICTED STOCK UNITS | −12,500 | 0 | ||
| 2019-11-22 | Chapman Marcus | Sale | −3,400 | $3.91 | $13K | 8,600 |
| 2019-11-01 | Chapman Marcus | Exercise or conversion | +12,000 | 12,000 | ||
| 2019-11-01 | Chapman Marcus | Exercise or conversion · Restricted Stock Units | −12,000 | 0 | ||
| 2019-08-05 | Berenson Stephen Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2019-06-18 | AFEYAN NOUBAR Director | Purchase | +4,444,444 | $2.25 | $10.0M | 4,444,444 |
| 2019-06-18 | AFEYAN NOUBAR Director | Purchase | +4,444,444 | $2.25 | $10.0M | 4,444,444 |
Page 24 of 34 · 662 trades